World Heart seeks US OK for LVAS (left ventricular assist system) conduit:
This article was originally published in Clinica
Executive Summary
World Heart has submitted a supplemental premarket approval application to the US FDA for permission to use its ePTFE inflow conduit as an alternative option for its Novacor left ventricular assist system (LVAS). European clinical trials of an earlier version of the conduit showed that it was linked with a reduction in stroke rate and that "many clinicians" preferred using it, said the Ottawa, Canada firm. The latest version of the conduit has undergone several design refinements and is already approved in Europe, the company added.